The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Prognostic factors of survival and rapid progression in782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d’Immunothérapie
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Motzer, R. J., Bander, N. H., & Nanus, D. M. (1996) · New England Journal of Medicine · doi:10.1056/nejm199609193351207 · Cited by 2,219
Survival and Prognostic Stratification of 670 Patients With Advanced Renal Cell Carcinoma
Motzer, R. J., Mazumdar, M., Bacik, J., Berg, W., Amsterdam, A., & Ferrara, J. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2530 · Cited by 1,801
Childs, R., Chernoff, A., Contentin, N., Bahceci, E., Schrump, D., Leitman, S., Read, E. J., Tisdale, J., Dunbar, C., Linehan, W. M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200009143431101 · Cited by 998
Negrier, S., Escudier, B., Lasset, C., Douillard, J.-Y., Savary, J., Chevreau, C., Ravaud, A., Mercatello, A., Peny, J., Mousseau, M., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199804303381805 · Cited by 967
Self-citation(1999) · The Lancet · doi:10.1016/s0140-6736(98)03544-2 · Cited by 601
Pyrhönen, S., Salminen, E., Ruutu, M., Lehtonen, T., Nurmi, M., Tammela, T., Juusela, H., Rintala, E., Hietanen, P., & Kellokumpu-Lehtinen, P.-L. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2859 · Cited by 441
Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.
Blay, J., Négrier, S., Combaret, V., Attali, S., Goillot, E., Merrouche, Y., Mercatello, A., Ravault, A., Tourani, J. M., & Jf, M. (1992) · PubMed · Cited by 420
Self-citation
Cited by
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
Hsieh, J. J., Purdue, M. P., Signoretti, S., Swanton, C., Albiges, L., Schmidinger, M., Heng, D. Y., Larkin, J., & Ficarra, V. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.9 · Cited by 2,426
Guideline for Management of the Clinical T1 Renal Mass
Campbell, S. C., Novick, A. C., Belldegrun, A., Blute, M. L., Chow, G. K., Derweesh, I. H., Faraday, M. M., Kaouk, J. H., Leveillee, R. J., Matin, S. F., et al. (2009) · Journal of Urology · doi:10.1016/j.juro.2009.07.004 · Cited by 1,831
Rini, B. I., Campbell, S. C., & Escudier, B. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60229-4 · Cited by 1,621
Self-citationHeng, D. Y., Xie, W., Regan, M. M., Harshman, L. C., Bjarnason, G. A., Vaishampayan, U. N., Mackenzie, M., Wood, L., Donskov, F., Tan, M.-H., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70559-4 · Cited by 1,030
Prognostic Factors for Survival in Previously Treated Patients With Metastatic Renal Cell Carcinoma
Motzer, R. J., Bacik, J., Schwartz, L. H., Reuter, V., Russo, P., Marion, S., & Mazumdar, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.132 · Cited by 793
Azab, B., Bhatt, V. R., Phookan, J., Murukutla, S., Kohn, N., Terjanian, T., & Widmann, W. D. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-011-1814-0 · Cited by 565
Mekhail, T. M., Abou-Jawde, R. M., BouMerhi, G., Malhi, S., Wood, L., Elson, P., & Bukowski, R. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.179 · Cited by 559
Jensen, H. K., Donskov, F., Marcussen, N., Nordsmark, M., Lundbeck, F., & von der Maase, H. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.9498 · Cited by 461
Ko, J. J., Xie, W., Kroeger, N., Lee, J.-L., Rini, B. I., Knox, J. J., Bjarnason, G. A., Srinivas, S., Pal, S. K., Yuasa, T., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71222-7 · Cited by 382
Teramukai, S., Kitano, T., Kishida, Y., Kawahara, M., Kubota, K., Komuta, K., Minato, K., Mio, T., Fujita, Y., Yonei, T., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2009.01.023 · Cited by 344
Bhatti, I., Peacock, O., Lloyd, G., Larvin, M., & Hall, R. I. (2010) · The American Journal of Surgery · doi:10.1016/j.amjsurg.2009.08.041 · Cited by 333
The neutrophil-to-lymphocyte ratio: a narrative review
Socorro Faria, S., Fernandes Jr, P. C., Barbosa Silva, M. J., Lima, V. C., Fontes, W., Freitas-Junior, R., Eterovic, A. K., & Forget, P. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2016.702 · Cited by 332
Schmidt, H., Bastholt, L., Geertsen, P., Christensen, I. J., Larsen, S., Gehl, J., & von der Maase, H. (2005) · British Journal of Cancer · doi:10.1038/sj.bjc.6602702 · Cited by 329
Prognostic Factors and Predictive Models in Renal Cell Carcinoma: A Contemporary Review
Sun, M., Shariat, S. F., Cheng, C., Ficarra, V., Murai, M., Oudard, S., Pantuck, A. J., Zigeuner, R., & Karakiewicz, P. I. (2011) · European Urology · doi:10.1016/j.eururo.2011.06.041 · Cited by 325
Impact of Immune Parameters on Long-Term Survival in Metastatic Renal Cell Carcinoma
Donskov, F., & von der Maase, H. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.9594 · Cited by 299
Immunomonitoring and prognostic relevance of neutrophils in clinical trials
Donskov, F. (2013) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2013.02.001 · Cited by 293
Prognostic factors and prognostic models for renal cell carcinoma: a literature review
Klatte, T., Rossi, S. H., & Stewart, G. D. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2309-4 · Cited by 273
Dutcher, J. P., de Souza, P., McDermott, D., Figlin, R. A., Berkenblit, A., Thiele, A., Krygowski, M., Strahs, A., Feingold, J., & Hudes, G. (2009) · Medical Oncology · doi:10.1007/s12032-009-9177-0 · Cited by 257
McKay, R. R., Kroeger, N., Xie, W., Lee, J.-L., Knox, J. J., Bjarnason, G. A., MacKenzie, M. J., Wood, L., Srinivas, S., Vaishampayan, U. N., et al. (2014) · European Urology · doi:10.1016/j.eururo.2013.08.012 · Cited by 253
Anti-VEGF therapies in the clinic
Meadows, K. L., & Hurwitz, H. I. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006577 · Cited by 237
“…differed with respect to prior treatment and percent of patients with favorable or unfavorable prognostic factors; comparator treatments also varied (best supportive care, interferon vs. new treatment, or interferon + new treatment) (Motzer et al. 2002; Negrier et al. 2002; Mekhail et al. 2005).”
Metadata
- Authors
- Négrier, S., Escudier, B., Gomez, F., Douillard, J.-Y., Ravaud, A., Chevreau, C., Buclon, M., Pérol, D., & Lasset, C.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2002-09
- Volume
- 13
- Issue
- 9
- Pages
- 1460-1468
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W2137822543
- Cited by
- 343
- References
- 14
- FWCI
- 9.39
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.